Literature DB >> 29190574

A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod.

Derek W Stitt1, Christopher J Boes2, Eoin P Flanagan3, Matthew T Howard4, Joseph P Colgan5.   

Abstract

The authors report a case of a 69-year-old woman with multiple sclerosis treated with fingolimod for duration of over one year who subsequently developed cutaneous large B cell lymphoma. There are few reported cases of lymphoma associated with fingolimod treatment for multiple sclerosis, but rates are higher than expected in the general population. The authors hope to promote awareness of the potential risk of this medication so that more diligent disease surveillance can be performed by both prescribing practitioners of fingolimod and their patients who receive it.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29190574     DOI: 10.1016/j.msard.2017.11.014

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  2 in total

1.  Primary central nervous system lymphoma in a patient with multiple sclerosis using fingolimod.

Authors:  Matheus Bernardon Morillos; Paulo Henrique Pires de Aguiar; Paulo Roberto Franceschini; Juliana Ávila Duarte; Cristian Daniel Piccini; Alessandro Finkelsztejn
Journal:  Neurol Sci       Date:  2022-08-29       Impact factor: 3.830

2.  Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients.

Authors:  Omar Hasan Ali; Fiamma Berner; Christoph Jakob Ackermann; Sandra Stephanie Ring; Alexandre Moulin; Joachim Müller; Eva Markert; Oltin Tiberiu Pop; Stefanie Müller; Stefan Diem; Thomas Hundsberger; Lukas Flatz
Journal:  Cancer Immunol Immunother       Date:  2020-08-17       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.